Evidence map›Paper›PMID 28275182›Full record

ArticleJournal of virology2017

Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model.

Keisuke Ojiro, Xiaowang Qu, Hyosun Cho, Jang-June Park, Annelise Vuidepot, Nikolai Lissin, Peter E Molloy, Alan Bennett, Bent K Jakobsen, David E Kaplan and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Keisuke OjiroCorporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
Xiaowang QuCorporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
Hyosun ChoCorporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
Jang-June ParkCorporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
Annelise VuidepotImmunocore Ltd., Abingdon, Oxfordshire, United Kingdom.
Nikolai LissinImmunocore Ltd., Abingdon, Oxfordshire, United Kingdom.
Peter E MolloyImmunocore Ltd., Abingdon, Oxfordshire, United Kingdom.
Alan BennettAdaptimmune Ltd., Abingdon, Oxfordshire, United Kingdom.
Bent K JakobsenImmunocore Ltd., Abingdon, Oxfordshire, United Kingdom.
David E KaplanCorporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
James L RileyUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Kyong-Mi ChangCorporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA kmchang@mail.med.upenn.edu.
University of Pennsylvania · USImmunocore (United Kingdom) · GBPhiladelphia VA Medical Center · USAdaptimmune (United Kingdom) · GB

Funding

TRANSGENIC AND CHIMERIC MOUSE COREP30DK050306 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Ken Hashigiwa Cadwell · 1997 to 2026
$32.5M
ZDV VS ZDV + DDL VS ZDV + DDL + NVP IN ASYMPTOMATIC HIV PATIENTSM01RR000040 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 1985 to 2006
$21.1M
Sequencing and Viral Evolution CoreU19AI117950 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WHERRY, E. JOHN · 2015 to 2019
$12.0M
Training In Tumor VirologyT32CA115299 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ROBERTSON, ERLE S. · 2006 to 2021
$4.7M
CELLULAR IMMUNITY--OUTCOME HEPATITIS C VIRUS INFECTIONR01AI047519 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI CHANG, KYONG-MI · 1999 to 2010
$3.1M
ALCOHOL/CELLULAR IMMUNITY IN HCV AND HIV INFECTIONR01AA012849 · NIAAA · UNIVERSITY OF PENNSYLVANIA · PI CHANG, KYONG-MI · 2000 to 2004
$1.9M
Mechanisms of Cellular Immune Dysfunction in Patients with Hepatitis C Virus andI01BX000649 · VA · PHILADELPHIA VA MEDICAL CENTER · PI CHANG, KYONG-MI · 2009 to 2013
–
BLRD VA I01 BX000649NCI NIH HHS T32 CA115299NCRR NIH HHS M01 RR000040NIAAA NIH HHS R01 AA012849NIAID NIH HHS R01 AI047519NIDDK NIH HHS P30 DK050306
6 · The paper itself

Abstract

The antiviral effects of hepatitis C virus (HCV)-specific CD8 T cells have been shown in an HCV replicon system but not in an authentic infectious HCV cell culture (HCVcc) system. Here, we developed tools to examine the antigenicity of HCV-infected HLA-A2-positive Huh7.5 hepatoma cells (Huh7.5A2 cells) in activating HCV-specific CD8 T cells and the downstream antiviral effects. Infectious HCV epitope mutants encoding the well-defined genotype 1a-derived HLA-A2-restricted HCV NS3-1073 or NS5-2594 epitope were generated from a genotype 2a-derived HCV clone (Jc1Gluc2A) by site-directed mutagenesis. CD8 T-cell lines specific for NS3-1073 and NS5-2594 were expanded from HCV-seropositive persons by peptide stimulation

Indexed as

B7-H1 AntigenCD8-Positive T-LymphocytesCell Line, TumorChemokine CCL4Coculture TechniquesCytotoxicity Tests, ImmunologicHepacivirusHepatocytesHLA-A2 AntigenHumansInterferon-gammaLymphocyte ActivationLysosomal-Associated Membrane Protein 1Mutagenesis, Site-DirectedPeptidesReceptors, Antigen, T-CellB7-H1 AntigenCD274 protein, humanChemokine CCL4HLA-A2 AntigenInterferon-gammaLysosomal-Associated Membrane Protein 1PeptidesReceptors, Antigen, T-CellTumor Necrosis Factor-alphaCD8 T cellscocultureHCV-specific TCRHuh7.5 cellslentiviral transductionPD-1 blockade

Identifiers

PMID28275182
PMCPMC5411593
OpenAlexW2592559588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.